CoChat

Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Open access
Huang, I-Chen, Chang, Tsui-San, Chen, Chiehfeng, Sung, Jia-Ying · 2022 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Background: Dementia and depression are increasingly common worldwide, and their effective control could ease the burden on economies, public health systems, and support networks. Vortioxetine is a new antidepressant with multipharmacologic actions that elevate the concentration of serotonin and modulate multiple neurotransmitter receptors in the brain. We conducted a meta-analysis to explore whether the cognitive function of patients with major depressive disorder (MDD) treated with vortioxetine would improve. Methods: We systematically reviewed randomized controlled trials (RCTs) in the PubMed, Embase, and Cochrane databases to assess the treatment effects of vortioxetine on the cognitive function of patients with MDD. The outcome measures included the Digit Symbol Substitution Test (DSST), Perceived Deficits Questionnaire (PDQ), and Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Pooled results were calculated using a fixed-effects or random-effects model according to the heterogeneity of the included trials. Results: Six RCTs with a total of 1782 patients were included in the meta-analysis, which demonstrated that vortioxetine improved DSST, PDQ, and MADRS scores in patients with MDD. The results were consistent at the 10- and 20-mg doses. In the 20-mg group, the decrease in MADRS scores was more significant than that in the placebo group. Conclusions: Both the 10- and 20-mg doses of vortioxetine can significantly increase DSST scores and decrease PDQ and MADRS scores in patients with MDD and cognitive dysfunction, but further studies with longer follow-up periods to assess mental function are required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyac054

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart of the search process to identify randomized controlled trials (RCTs) for the meta-analysis.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart of the search process to identify randomized controlled trials (RCTs) for the meta-analysis.CC BY-NC · PubMed Central
Figure 2. Risk-of-bias assessment for the randomized controlled trials.
Figure 2. Risk-of-bias assessment for the randomized controlled trials.CC BY-NC · PubMed Central
Figure 3. Change in Digital Symbol Substitution Test scores from baseline. CI, confidence interval; SMD, standardized mean difference.
Figure 3. Change in Digital Symbol Substitution Test scores from baseline. CI, confidence interval; SMD, standardized mean difference.CC BY-NC · PubMed Central
Figure 4. Change in Perceived Deficits Questionnaire scores from baseline. CI, confidence interval; SMD, standardized mean difference.
Figure 4. Change in Perceived Deficits Questionnaire scores from baseline. CI, confidence interval; SMD, standardized mean difference.CC BY-NC · PubMed Central
Figure 5. Change in Montgomery-Åsberg Depression Rating Scale scores from baseline. CI, confidence interval; WMD, weighted mean difference.
Figure 5. Change in Montgomery-Åsberg Depression Rating Scale scores from baseline. CI, confidence interval; WMD, weighted mean difference.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 4

  1. American Psychiatric Association, 2013, Neurocognitive disorders., 591
  2. Butterworth, 2020, Guidelines for the pharmacological management of dementia, p., 17
  3. McQuaid, 2019, APA Guideline for the Treatment of Depression; chap: discussion of clinical recommendations, 39
  4. World Health Organization, 2021, Dementia

Cited by

See all 41

Metadata

Authors
Huang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y.
Affiliations
Wan Fang Hospital (TW)
Corresponding author
Sung, Jia-Ying
Venue
International Journal of Neuropsychopharmacology
Published
2022-08-19
Volume
25
Issue
12
Pages
969-978
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W4293790530
Cited by
41
References
53
Citations by year
2026: 8 · 2025: 16 · 2024: 11 · 2023: 6
FWCI
1.19
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Wan Fang Hospital, Taipei Medical University (110TMU-WFH-13)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
vortioxetine, major depressive disorder, cognitive impairment, cognitive function, antidepressants, serotonin, Digit Symbol Substitution Test, Montgomery-Asberg Depression Rating Scale, dose comparison
MeSH terms
Vortioxetine, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Humans, Piperazines, Sulfides, Randomized Controlled Trials as Topic, Treatment Outcome, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.